Key Insights on Genmab A/S ADS – A Stock Overview

By Tamara Parker • Tuesday, October 28 10:06 • Permanent Link

Large-cap Health Care company Genmab A/S ADS has moved -0.4% so far today on a volume of 415,028, compared to its average of 1,919,329. In contrast, the S&P 500 index moved 0.0%.

Genmab A/S ADS trades -23.14% away from its average analyst target price of $37.61 per share. The 7 analysts following the stock have set target prices ranging from $27.5 to $49.0, and on average have given Genmab A/S ADS a rating of buy.

Anyone interested in buying GMAB should be aware of the facts below:

Genmab A/S ADS's current price is -96.7% below its Graham number of $881.38, which implies the stock has a margin of safety
Genmab A/S ADS has moved 25.6% over the last year, and the S&P 500 logged a change of 17.9%
Based on its trailing earnings per share of 1.93, Genmab A/S ADS has a trailing 12 month Price to Earnings (P/E) ratio of 15.0 while the S&P 500 average is 29.3
GMAB has a forward P/E ratio of 20.7 based on its forward 12 month price to earnings (EPS) of $1.4 per share
Its Price to Book (P/B) ratio is 0.34 compared to its sector average of 3.19
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Based in Copenhagen, the company has 2,639 full time employees and a market cap of $17.85 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.